CARAMELLA C, Texier M, Valette CA, Tessonnier L, Mezquita L, Lahmar J, Mazieres J, Zalcman G, Brosseau S, Westeel V, Moulec SL, Leroy L, Duchemann B, Veillon R, Planchard D, Boucher M, Koscielny S, Soria J, Bess B: hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)